Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Enkosi Mondleki"'
Autor:
Teboho Mooko, Feziwe Busiswa Bisiwe, Enkosi Mondleki, Molefi Daniel Morobadi, Perpetual Chikobvu, Martin Munene Nyaga, Asis Bala, Dominique Goedhals, Thabiso Rafaki Petrus Mofokeng, Gabre Kemp, Kwazi Celani Zwakele Ndlovu
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-10 (2024)
Abstract Background Renally adjusted lamivudine dosages are effective. However, some of the kidney failure patients managed with lamivudine-containing regimens are failing to suppress HIV in peritoneal dialysis (CAPD) effluent. The steady-state lamiv
Externí odkaz:
https://doaj.org/article/e03cf1ddb452451ca4e746bd3b97905c
Autor:
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi
Publikováno v:
Southern African Journal of HIV Medicine, Vol 23, Iss 1, Pp e1-e6 (2022)
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women. Understanding dolutegravir exposu
Externí odkaz:
https://doaj.org/article/a6629d34d35249ea887fd4b45fa2b85c
Autor:
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi
Publikováno v:
Southern African Journal of HIV Medicine; Vol. 23 No. 1 (2022)
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women. Understanding dolutegravir exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a73237887b2164db7afaad7ece73787
https://www.ajol.info/index.php/sajhivm/article/view/242036
https://www.ajol.info/index.php/sajhivm/article/view/242036
Autor:
Karen J. Barnes, Rephaim Mpofu, Marc Blockman, Clifford George Banda, Gayle Tatz, Phumla Sinxadi, Hannah Gunter, Enkosi Mondleki, Karen Cohen
Although chloroquine and hydroxychloroquine have not yet been shown to be safe or effective for the treatment or prevention of COVID-19, regulatory agencies in some countries have authorised their use in Coronavirus disease 2019 (COVID-19) due to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f07d20de89c10aaacf50b10ac82eb14
https://doi.org/10.14293/111.000/000008.v1
https://doi.org/10.14293/111.000/000008.v1
